Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Amazing how many analysts on this board

<< Previous

Bullboard Posts

Next >>

Comment by Polaris570on Dec 15, 2020 4:31pm

289 Views

Post# 32111645

RE:Amazing how many analysts on this board

Nobody can predict were its going tomorrow and don't even know what the hell you are talking about. Hope your still green Redboy. Hope the bleeding is done because I'm in the green with 742 shares that I picked up just before close as soon as it hit 4.20$. GLTA

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China